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Abstract
 .After exposure of bovine aortic endothelial cells to various small peptides tetra- to undeca-mer , extensive transport of
the peptides across the plasma membrane was observed in the concentration range 10y7 to 10y2 M. The observed transport
events, which contradict the generally anticipated poor permeability of peptides across plasma membranes, exhibited high
complexity and showed no saturability up to a concentration of 10y2 M. Evidence was found for the involvement of
mdrp-like transporters as well as of energy-independent facilitated diffusion events. The peptide levels within the cells
approximated those of the incubation solution within 30 min, indicating high capacity and velocity for the involved
transport processes. Correspondingly, preloaded cells exported about 80% of the internalized peptide within 5 min at 378C.
Analogous results were found after peptide exposure to several other mammalian cell types, indicating a more general
importance of the transport phenomena described here. Our findings contradict the prevailing opinion that the often
observed lack of activity of externally administered peptides against their targets within intact cells is accounted for
primarily by poor cellular uptake and point to export processes counteracting the uptake to be more important in this
context. q 1997 Elsevier Science B.V.
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1. Introduction
The value of small peptides as biological agents is
compromised according to the prevailing opinion,
apart from metabolic instability, primarily by poor
w xpermeability across biological membranes 1–3 .
Metabolic degradation appears to be of lesser impor-
tance in this context, since there exist multiple ap-
proaches to improve the enzymatic stability of pep-
tides. To overcome the poor propensity of peptides to
cross lipidic membranes, however, provides principal
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problems. Besides insufficient lipophilicity, this low
permeability is accounted for primarily by the high
hydrogen-bonding potential of the peptide backbone’s
w xamide groups 4 , which often cannot be reduced by
structural alterations without affecting the affinity for
the biological target. Numerous attempts to improve
the permeability by simply increasing the lipophilic-
w xity of the molecule have not met with success 5 .
The existence of peptide carriers in the plasma
membrane of mammalian cells, which could circum-
vent this principal obstacle, has been demonstrated to
w xdate only for di- and tripeptides 6,7 . Additionally,
evidence has been provided for the presence of pep-
tide transporters at the blood–brain barrier, exhibit-
ing, however, high structural specificity for a limited
w xnumber of centrally active peptides 8,9 .
In this study, we found evidence that, in contrast
to prevailing opinion, oligopeptides tetra- to at least
.undeca-mers can extensively and non-specifically
cross the plasma membranes of mammalian cells.
Our findings point to the presence of multiple trans-
port facilities for oligopeptides in the plasma mem-
brane of mammalian cells which, if considering coun-
teracting export processes, appear exploitable for
non-specifically translocating oligopeptides into liv-
ing cells. Such a possibility seems to be of particular
interest with respect to an introduction into intact
cells of small peptides that have appropriate se-
quences for blocking associations between signal-
w xtransducing proteins 10 . So far, competition experi-
ments of this kind have only been carried out in cell
free systems, permeabilized cells or by means of
microinjection techniques.
2. Materials and methods
2.1. Materials
3  .H-DAMGO and 5 6 -carboxyfluorescein-N-
 .hydroxysuccinimide ester FLUOS were purchased
from Amersham and Boehringer, Mannheim, respec-
tively. DNP-SG was synthesized according to Hinch-
w x  .man et al. 11 . Buserelin HOE 766 was a generous
 .gift from Dr. J. Sandow Hoechst . Other chemicals
and reagents, if not specified, were purchased from
Sigma or Bachem.
2.2. Peptide synthesis
The peptides were synthesized manually by the
solid phase method using standard Fmoc chemistry.
 .Boc-Lys Fmoc -OH was coupled to o-chloro-trityl
resin in the presence of two equivalents of ethyl-di-
isopropylamine. After Fmoc-deprotection by 20%
 .piperidinerdimethylformamide DMF , subsequent
couplings of Fmoc-Leu, Fmoc-Phe, Fmoc-Gly and
 .Fmoc-Tyr tBu were carried out by means of TBPipU
w x12 . The crude peptide was obtained from the final
cleavage in acetic acid–trifluoroethanol–methylene
 .dichloride 2:2:6, vrvrv for 1 h and purified using
preparative reversed-phase high-performance liquid
 . chromatography RP-HPLC . The peptide purity )
. 98% was determined by analytical RP-HPLC 220
.nm and the identity was confirmed by electrospray
mass spectrometry.
 .Nitrobenzoxadiazole NBD - and FLUOS-deriva-
tives were obtained by reacting the Fmoc-deprotected
resin-bound peptides with two equivalents of 7-
 .chloro-4-nitrobenz-2-oxa-1,3-diazole or 5 6 -
carboxyfluorescein-N-hydroxysuccinimide ester, re-
spectively, for about 48 h at pH 8–9 and ambient
temperature.
2.3. Tritiated peptides
w3 xWith the exception of H DAMGO, which was
purchased from Amersham, the tritiated peptides were
w xsynthesized as described previously 13–15 . Before
use, the labelled peptides, all exhibiting specific ra-
dioactivities of about 1 Tbqrmmol, were cleaned up
by HPLC to a radioactive purity)95% and were
mixed with the respective inactive parent compound
to attain the required peptide concentration.
2.4. Cell culture
 .Calf aortic endothelial cells BkEz-7; AEC , a
12.–20. subculture of a cell line that was established
w xand characterized by Halle et al. 16 , were cultured
 .to almost confluency four days in 24-well plates
 5 .10 cellsrwell at 378C in a humidified 3% CO in2
air environment in Dulbecco’s modified Eagle’s
 .  .medium DMEM Biochrom, Berlin, Germany con-
taining 4.5 mgrml of glucose, 100 Urml of peni-
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cillin, 100 mgrml streptomycin and supplemented
with 290 mgrl glutamine and 10% fetal bovine
 .serum FBS; Sigma, Deisenhofen, Germany .
 .Porcine endothelial cells SEZ; MEMr5% FBS ,
human endothelial cells ECV 304; M199r10% heat
.inactivated FBS , murine corticotrophic pituitary tu-
 .mour cells AtT-20; DMEMr10% FBS , human neu-
roblastoma cells SK-N-SH; MEM Eagle’sr10% FBS
supplemented with 1% non-essential amino acids, 1%
 .sodium pyruvate and 1% glutamine Biochrom , hu-
man embryonic kidney tumour cells HEK; MEM
Earle’sr10% FBS supplemented with 1% non-essen-
. tial amino acids and human hepatoma cells Hep G2;
MEM Eagle’sr10% FBS supplemented with 1%
non-essential amino acids, 1% sodium pyruvate and
.1% glutamine were cultured analogously.
 .Brain microvessel endothelial cells BEC were
isolated from fresh porcine brains, as described by
w xMertsch et al. 17 . The cells were plated into 24-well
plates at an initial density of 5P104 cellsrwell and
were cultured as outlined for AEC. In addition, the
wells were coated with gelatine Sigma, St. Louis,
.MO, USA before plating and 1 ngrml basic fibro-
 .blast growth factor Promega, Madison, WI, USA ,
100 mgrml Heparin H-3149, Sigma, St. Louis, MO,
.  .USA and 0.5 mgrml amphotericin Biochrom were
added to the medium. The obtained monolayers
proved to be more than 95% endothelial in origin and
exhibited properties regarded to be typical for the
blood–brain barrier presence of tight junctions, g-
glutamyl transpeptidase-, alkaline phosphatase- and
angiotensin-converting enzyme activities, Factor VIII
. w xantigen 17 .
2.5. Uptake experiments
After removing the culture medium, the cells were
rinsed twice at 378C with PBS–Dulbecco’s Bio-
.  .chrom , supplemented with 1 grl glucose DPBSG
and subsequently exposed to the substrates dissolved
 .in DPBSG 150 mlrwell for the indicated periods.
Subsequently, the substrate solution was aspirated off
and the cells were washed four times with ice cold
 .PBS within 2 min and lysed by allowing them to
stand for about 20 h at room temperature in a 0.1%
solution of Triton X-100 containing 10 mM trifluoro-
 .acetic acid 200 mlrwell . For performing efflux
experiments, the preloaded and washed cells were
 .incubated with DPBSG 200 mlrwell at 378C for
indicated periods prior to lysis. For determination of
the acid-sensitive bound proportion of cell-associated
peptide, in some cases, an acid-wash step incubation
with 200 mlrwell of 0.2 M acetic acidr0.05 M NaCl
.for 5 min at 08C was inserted between the normal
wash process and lysis. The obtained extracts or
lysates were utilized without further treatment for
HPLC quantitation or liquid scintillation counting.
Parts of the Triton-lysates were used for determin-
ing the protein content, according to the method of
w xBradford 18 . In order to correlate the amount of
protein with cell number, monolayers, grown under
identical conditions in separate wells, were trypsinized
and counted. For AEC, a ratio of 200 mg proteinr106
cells was found by this procedure. The average vol-
ume of AEC was determined to be 1.4 pl by means of
a coulter-ZM counter Coulter Electronics, Luton,
.UK .
2.6. HPLC analysis
HPLC was performed using a Bischoff HPLC
 .gradient system Leonberg, Germany equipped with
a Kromasil 100 C , 5-mm column 250=4 mm18
.I.D. , precolumns containing the same sorbent and a
Rheodyne-RH 8125 injection valve with a 50-ml
sample loop. The elution was performed with 0.01 M
 .  .trifluoroacetic acid TFA A and acetonitrile–water
 .  . 9:1, vrv B gradient from 30 to 60% B within 20
.min . Detection was performed by fluorescence using
 .a fluorescence detector RF-551 Shimadzu, Japan at
520 nm after excitation at 445 nm for prepurified
 .FLUOS-labelled peptides see below , at 350 nm
after excitation at 285 nm for tryptophan-containing
peptides and at 540 nm after excitation at 470 nm for
NBD-labelled derivatives. The peaks corresponding
to the intact peptides and their des-tyrosine metabo-
lites were quantified using a Hyperdata Integration
 .Workstation S I Bischoff, Leonberg, Germany on
the basis of calibration lines established previously
with pure references. If not specified otherwise, the
so-determined quantities of incorporated peptide are
generally indicated as the sum of intact peptide and
detyrosinated metabolite.
The cells’ own fluorescently active components
did not interfere with detection of the peptides, even
in the case of tryptophan-containing derivatives, so
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that pretreatment of the cell lysates could be avoided
at the cost of a somewhat more frequent replacement
of the precolumn.
2.7. FLUOS deri˝atization
To 70 ml of the sample solution, 10 ml of 2 M
K HP0 , 10 ml of 23 mM cyclohexylalanine solution2 4
 .internal standard and 5 ml of a solution containing
 .4.9 mg of 5 6 -carboxyfluorescein-N-hydroxysucci-
 .nimide ester Boehringer in 100 ml of dimethylsulf-
oxide were added and allowed to react for about 20 h
at room temperature. Subsequently, the solution was
mixed with 4 ml of 8 M NaOH and, after standing for
at least 30 min, with 11 ml of 1.4 M H PO . HPLC3 4
was first carried out by eluting with 0.04 M phos-
 . phate buffer, pH 7.4 A and acetonitrile–water 9:1,
.  .  .vrv B with gradients from 9–28% B 0–20 min
 .and 28–85% B 20–30 min at a flow-rate of 1.0
mlrmin. UV Detection was at 242 nm. The eluates
containing the derivatized peptides and their amino-
 .peptidase degradation products 16 to 21 min were
collected and concentrated to dryness by means of a
vacuum centrifugal evaporator Jouan, Unterhaching,
.Germany . Residuals, corresponding to 1 ml of the
eluate, were dissolved in 100 ml of 0.5 M TFA
containing 25% acetonitrile and subjected to the
HPLC protocol described above for quantitation.
( )2.8. Confocal laser scanning microscopy CLSM
 4.Cells 1P10 were plated on 22=22 mm cover-
slips, glued with silicones RTV 615Ar615B, Paul
. Hellermann, Pinneberg, Germany above the hole 15
. mm D of punched plastic Costar culture dishes 35
.mm D; Integra Biosciences, Germany and cultured
for four days, as described above. After removing the
culture medium, the cells were exposed to solutions
of the fluorescently labelled peptides in DPBSG 10–
.500 mM for 60 min at 378C. Subsequently, the cells
were washed four times with ice-cold PBS and cov-
ered with about 200 ml of PBS. Microscopy was
conducted within 10 min at room temperature using
an LSM 410 inverted confocal laser scanning micro-
 .scope Carl Zeiss Jena, Jena, Germany . Excitation
was performed at 488 nm by means of an argon–
 .krypton laser and a dichroitic mirror FT 510 for
wavelength selection. Emission was measured at 515
 .nm using a cut-off filter LP 515 in front of the
detector. For optical sectioning in the z-direction,
sixteen frames were made, with a thickness of 1 mm.
Subsequent HPLC investigations of the incubation
solution and of Triton X-100 lysates of the cells gave
no indication of any metabolic breakdown of the
peptides.
3. Results
3.1. E˝idence for peptide incorporation after millimo-
lar exposure of endothelial cells to enkephalin-de-
ri˝ed peptides
With the initial intention of examining the possibil-
ity of whether or not natural amino acid transporters
could be exploited for translocating small central
active peptides through the blood–brain barrier, we
 .exposed aortic- AEC and brain microvessel en-
 .dothelial cells BEC to several enkephalin-derived
peptides. Surprisingly, in all cases, we observed high
 .degrees of peptide association onto the cells Fig. 1 .
Incubation at 0–48C 2 mM peptide, 60 min; precool-
.ing the cells for 30 min resulted in virtually no
 .association to the cells -0.1 nmolrmg protein so
that non-specific adsorption could be ruled out as
contributing noticeably and actual uptake into the cell
interior had to be taken into consideration.
Since both derivatives bearing an intact a-carboxy-
and a-amino group for recognition by amino acid
Fig. 1. Quantity of cell-associated peptide after exposure of aortic
endothelial cells to 2 mM solutions of various enkephalin-derived
peptides in DPBSG for 30 min at 378C. Each bar represents the
mean of three samples"SEM.
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w x.transporters, according to Smith 19 and unmodified
peptides exhibited comparable degrees of association
 .to the cells Fig. 1 , the observed peptide uptake
appeared to resemble more general phenomena, un-
like our initial intention. Therefore, we extended our
investigations with the goal of gaining insights into
the mode and structural requirements for the transport
events that were found.
In order to facilitate detection and to render the
degree of degradation by plasma membrane-associ-
ated peptidases negligible, millimolar peptide concen-
 .trations 0.2–10 mM were employed in the first
experiments. That the observed transport phenomena
did not reflect artifacts, accounted for by these un-
physiologically high peptide concentrations, was as-
certained in subsequent investigations conducted in
the low micromolar range using tritium-labelled pep-
 .tides see below .
3.2. Time dependency of peptide translocation
The uptake by the cells reached an equilibrium at
 .about 20 min Fig. 2 . The efflux out of preloaded
cells exhibited a complex course, indicating location
of the cell-associated substrate within distinct com-
 .partments Fig. 3 . From BEC, the release of the
incorporated substrate proceeded considerably more
 .rapidly than that from AEC Fig. 3 , suggesting a
relation to the lower degree of uptake into BEC Fig.
.3 .
3.3. Influence of the peptide structure on cellular
uptake
In order to obtain information about the structural
requirements for the found peptide import, we modi-
fied the N- and C-terminal amino- and carboxy-groups
of Leu-enkephalin, respectively, and incorporated ba-
sic and acidic residues and glycine into the N-termi-
nal, C-terminal and middle regions of the molecule.
Phenylalanine was generally replaced by tryptophan
in this series to permit fluorescence detection during
HPLC analysis. Since amidation of the C-terminus
did not attenuate the uptake, in most cases, the more
 .conveniently available amides were used Table .
The performed structural modifications only
 .slightly influenced peptide import Table , indicating
poor structural specificity for the transport mecha-
Fig. 2. Quantity of cell-associated peptide after exposing AEC to
2 mM YGGFL-e-K at 378C for different periods of time. Each
point represents the mean of three samples"SEM.
nism. Generally, a positive effect of basic modifica-
tion and, more surprisingly, of incorporation of
glycine, is suggested by the data displayed in Table
1.
3.4. CLSM imaging after cell exposure to fluores-
cently labelled peptides
The poor structural specificity that was found
should justify the use of N-terminally fluorescently
labelled derivatives for directly demonstrating pep-
tide uptake by CLSM, in spite of substantial alter-
ations to the charge and lipophilicity, which were
associated with the introduction of fluorescence la-
bels into peptides. We, therefore, performed CLSM
Fig. 3. Liberation of cell-associated peptide at 378C from AEC
and BEC, which had been previously exposed to 2 mM YGGFL-
e-K for 60 min at 378C. Each point represents the mean of three
samples"SEM.
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with AEC that had been previously exposed to the
fluorescently labelled peptides NBD-GGFL, NBD-
GGFL-e-K, NBD-RR-all-D-LWGGY-NH and all-2
 . D-RPRPQQFO- FLUOS GLM-NH all-D-FLUOS-2
.SP . The CLSM images in all cases revealed actual
peptide import into the cell interior and exhibited a
similar pattern to that displayed by NBD-GGFL in
Fig. 4. Analogous results to those found with AEC
 .were also obtained with BEC NBD-GGFL-e-K , pri-
mary hypophysis cells NBD-RR-all-D-LWGGY-
. NH ; Furkert et al., in prep. and mast cells FLUOS-2
. SP and all-D-FLUOS-SP; Lorenz et al., in prep not
.shown .
3.5. Cell ˝iability and peptide degradation
No differences were detectable between controls
and cells treated with 2 mM peptide according to the
protocol outlined above with respect to trypan blue
w xexclusion and the MTT-viability test 20 .
Due to the high peptide concentrations used, the
proportion of the peptide that was degraded by pepti-
dases during exposure to the cells remained clearly
Table 1
Quantity of cell-associated substrate after exposure of aortic
endothelial cells to various enkephalin-derived peptides a
Peptide nmolrmg protein
 .YGGFL 0.57 "0.13
 .YGGWL 0.60 "0.17
 .N-Methyl-GYGGWL-NH 0.71 "0.052
 .N-Dimethyl-GYGGWL-NH 0.63 "0.192
 .SuccinylYGGWL-NH 0.80 "0.042
 .YGGWLE-NH 0.67 "0.132
 .DAMGO 0.89 "0.09
 .AcYGGWL-NH 0.97 "0.222
 .YGGWL-NH 1.12 "0.112
 .EYGGWL-NH 1.30 "0.132
 .GYGGWL-NH 1.29 "0.262
 .all-D-YGGWL-NH 1.48 "0.272
 .YGGEWL-NH 1.61 "0.192
 .RYGGWL-NH 1.65 "0.562
 .KYGGWL-NH 1.90 "0.082
 .AcKYGGWL-NH 1.85 "0.272
 .YGGWLR-NH 1.98 "0.232
 .YGGRWL-NH 2.12 "0.652
 .all-D-LWGGY-NH 2.56 "0.362
 .YGGWLG-NH 2.40 "0.262
 .YGGGWL-NH 2.99 "0.242
a Incubation with 2 mM peptide dissolved in DPBSG for 30 min
 .at 378C mean of three samples"SEM .
Fig. 4. Confocal laser scanning microscopy image of a 1-mm
thick central horizontal optical section through AEC that had
previously been exposed to 0.7 mM NBD-GGFL in DPBSG for
30 min at 378C. Inset: The same section viewed in transmission
mode.
below 10%, so that the influence of enzymatic break-
down upon the uptake was neglected. Correspond-
ingly, the addition of 0.4 mM bestatin, a potent
inhibitor of aminopeptidase N, the predominant pepti-
w xdase activity residing on the surface of AEC 21,22 ,
did not influence the amount of cell-associated pep-
tide under the conditions used in this study.
In order to obtain information about the possible
effects of endogenous peptidases on the internalized
substrate, YGGFL-e-K and YGGFL were exposed to
Triton X-100 lysates of AEC or BEC at pH 7.2
w 51P10 cells, 1% Triton X-100 in 0.5 ml PBS–H O2
 . x1r9, vrv ; 0.2 mM peptide; 60 min, 378C . The
modified peptide proved to be substantially more
stable than leucine enkephalin under these conditions.
About 50% of YGGFL-e-K remained intact, whereas
95% of YGGFL was degraded. After exposure of the
cells to acidic lysates 10 mM TFA in 0.1% Triton
.X-100 , no cleavage of the peptides could be detected
within 24 h at ambient temperature.
3.6. Reproduction of the translocation e˝ents in the
micromolar range
Beside the metabolically stable enkephalin analog,
w3 xH DAMGO, we utilized several tritiated peptides
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Fig. 5. Quantity of cell-associated peptide after exposing AEC to
different concentrations of tritiated DAMGO for 30 min at 378C.
Each point represents the mean of three samples"SEM.
that differed with respect to charge, size and modifi-
 w3 xcation of the N- or C-terminus R-P-K-P-G- H Y-
w3 x w3 xOH; R-K-E-V- H Y-OH; AcR-AcK-E-V- H Y-OH
w3 x .and H buserelin for conducting transport experi-
ments in the micromolar concentration range, in a
manner analogous to that used in the millimolar
range.
To minimize the influences of enzymatic degrada-
tion, we generally performed the uptake experiments
in the presence of 0.2 mM bestatin. Under these
conditions, more than 90% of the radioactivity in the
 .incubation solution was attributable by HPLC to the
intact peptide after exposure to the cells. From the
cell-associated peptide portion, at least 40% coeluted
with the intact peptide during subsequent HPLC anal-
ysis, indicating uptake of the intact peptide.
3.7. Concentration dependency of uptake
The uptake of the enkephalin analog, DAMGO,
into AEC proved to be linear from 10y2 up to 10y7
 .M Fig. 5 , rendering peculiarities for the high con-
centration range unlikely. Uptake investigations per-
formed with the other labelled and unlabelled pep-
tides in the range 5P10y4 to 10y7 M and from 10y2
y4  .to 2P10 M led to analogous results not shown .
Generally, the quantities of internalized peptide
approached values corresponding to an equilibrium
between intra- and extracellular peptide concentra-
tions taking into account the cell volume of 1.4 pl
Fig. 6. Quantity of cell-associated peptide after exposing AEC, pretreated with DPBSG or 25 mM 2-deoxyglucose–10 mM sodium azide
in DPBS, respectively, for 60 min at 37 and 08C, to 10 mM tritiated peptide in DPBSG without additives and in the presence of 25 mM
 .2-deoxyglucose–10 mM sodium azide in DPBS, 20 mM vincristine in DPBSG, 100 mM 2,4-dinitrophenyl-S-glutathione DNP-SG in
 .DPBSG and 100 mM sulfobromophthalein BSP in DPBSG for 60 min at 37 and 08C. Each bar represents the mean of three
samples"SEM. The differences between the respective controls and the asterisk-labelled bars are statistically significant at PF0.05
 .Student’s t-test .
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and the protein content of 200 mg proteinr106 cells
.given in the Section 2 .
3.8. Influences of metabolic and transport inhibitors
To gain an insight into the mechanism of the
observed peptide uptake, we exposed the cells to the
peptides in the presence of various agents that are
known to affect metabolism and transport events.
Energy depletion and treatment with vincristine, an
inhibitor of the multidrug resistance mediating efflux
w xpump, P-glycoprotein 23 , in most cases resulted in a
 .slight reduction in uptake Fig. 6 . The presence of
 .DNP-S-glutathione DNP-SG and bromosulfoph-
thalein, known to serve as substrates for multidrug
resistance-associated protein, glutathione conjugates-
w xand large anion transporters 24–27 , augmented or
attenuated, respectively, the peptide incorporation,
 .depending on the respective substrate Fig. 6 . This
complex behaviour suggests the involvement of mul-
tiple energy-consuming transporters exhibiting dis-
tinct preferences for the inward or outward direction,
respectively, and prevents clear kinetic characteriza-
tion.
That these reagents also influence the efflux out of
the cells is illustrated in Fig. 7 for DNP-SG-treated
cells. Conclusions concerning the reduced efflux rate
in the presence of DNP-SG, which is apparent in Fig.
Fig. 7. Liberation of cell-associated peptide at 378C from AEC
into DPBSG without additives and in the presence of 100 mM
 .2,4-dinitrophenyl-S-glutathione DNP-SG , exposed previously to
10 mM tritiated DAMGO for 60 min at 378C alone or in the
presence of 100 mM DNP-SG, respectively. Each point repre-
sents the mean of three samples"SEM.
7 for the period from 5 to 30 min, and its relation to
the enhanced uptake, can be drawn, however, only
with caution. Because of a delayed onset of the
effects, the agents had to be added prior to the
preloading of cells, which resulted in different pep-
tide levels for control- and reagent-treated cells and,
probably, in the occupation of distinct compartments
by the peptides.
Brefeldin A, an inhibitor of vesicular transport
w x 28 , did not significantly affect the uptake not
.shown , which argues against considerable contribu-
tions being made by endocytic processes.
The major part of the observed peptide uptake,
however, remained uninfluenced by energy depletion
and, therefore, must proceed in an energy indepen-
 .dent way Fig. 6 . The substantially reduced uptake at
08C renders simple diffusion as unlikely to be in-
volved and points to facilitated diffusion as the mech-
anism for this energy-independent transport. Evi-
dence for cotransport of protons or Naq, however,
w xoften found associated with such a mechanism 29 ,
could not be found. Alterations of the pH in the range
of 7.2–5.5, treatment with the acidotropic agent,
 . w x qmonensin 20 mM 30 , and replacement of Na by
choline, performed in this context, had no effect on
 .peptide uptake not shown .
3.9. Discrimination between acid-sensiti˝e and acid-
resistant portions of cell-associated peptide by acid
washes
The levels of cell-associated peptide attained after
 .incubation with 10 mM peptide at 0–48C Fig. 6
were relatively higher than those found in the mil-
limolar concentration range, suggesting enhanced
contributions of non-specific adsorption in the low
concentration range. To obtain information about the
degree of this non-specific adsorption, we performed
an additional wash step with acetic acid–NaCl for 5
min at 08C, commonly thought to strip off adsorbed
w xpeptides 31 . Fig. 8 displays the cell-associated pep-
tide, which was split into acid-sensitive and an acid-
 . resistant internalized parts. Generally except for
.RPKPGY at 08C , the acid-sensitive portion remained
clearly below 50% of the total amount, which argues
for an actual uptake of the greater part of the ob-
served cell-associated peptide. Moreover, the signifi-
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cant reduction in the acid-sensitive bound peptide
portion observed in several cases after energy deple-
 .tion Fig. 8 raises questions regarding the assump-
tion that the acid extract contains only surface-bound
peptide. More likely, this finding suggests export
from the cell interior, proceeding also throughout the
extraction period at 08C. That the cells exert residual
transport activities at 08C is also suggested by the
considerable amount of acid-resistant bound internal-
.ized peptide found after incubation at this tempera-
 .ture Fig. 8 .
3.10. Reproducing the transport e˝ents with other
cell types
In order to rule out the possibility that the found
transport phenomena would reflect a peculiarity of
AEC, we exposed several cell lines originating from
different species and tissues to 10 mM tritiated
DAMGO at 378C and 08C and after energy depletion.
The results of these experiments are displayed in Fig.
Fig. 8. Acid-sensitive and acid-resistant quantities of cell-associ-
ated peptide after exposing AEC, pretreated with DPBSG or 25
mM 2-deoxyglucose–10 mM sodium azide in DPBS, respec-
tively, for 60 min at 37 and 08C, to 10 mM tritiated peptide in
DPBSG without additives and in the presence of 25 mM 2-de-
oxyglucose–10 mM sodium azide in DPBS for 60 min at 37 and
08C. The acid-sensitive and acid-resistant proportions of the
cell-associated peptide were assessed after incubating the washed
cells in 0.2 M acetic acid containing 0.05 M NaCl for 5 min at
08C before lysing the cells and measuring the radioactivities of
both the acid extract and the lysate. Each bar represents the mean
of three samples"SEM. The differences between the respective
controls and the asterisk-labelled bars are statistically significant
 .at P F0.05 Student’s t-test .
Fig. 9. Acid-sensitive and acid-resistant quantities of cell-associ-
ated peptide after exposing various cell types originating from
different species and organs to 10 mM tritiated DAMGO, accord-
ing to the conditions specified in the legend to Fig. 8. Each bar
represents the mean of three samples"SEM. The differences
between the respective controls and the asterisk-labelled bars are
 .statistically significant at P F0.05 Student’s t-test .
9 and reveal, despite clear quantitative differences,
considerable analogy to that found previously with
AEC. This finding supports the notion that the ob-
served transport phenomena would reflect a more
general behaviour of mammalian cells, which has
been suggested also by the above outlined analogies
found between the results obtained with AEC and
BEC, respectively, in the millimolar range, and of
AEC and various cell types in CLSM studies.
4. Discussion
This study provides evidence that oligopeptides
containing more than five amino acid residues are
capable of extensively crossing plasma membranes of
living cells. So far, such an ability was demonstrated
w xonly for di- and tripeptides 6,32,33 and for a limited
number of oligopeptides possessing specific trans-
w xporters at the blood–brain barrier 8,9 .
Our findings contradict prevailing opinion that the
repeatedly reported inefficiency of externally admin-
istered oligopeptides against recognition domains of
signal proteins or intracellular enzymes would be
accounted for primarily by poor permeability of pep-
tides across the plasma membranes and point to
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export processes being a more decisive factor in this
context.
This notion appears reconcilable with recent specu-
lation about the residence of, as yet undetected, pep-
tide transporters of the ABC-transporter type in the
plasma membrane of mammalian cells being opera-
w xtive preferably as efflux pumps 34–36 . The influ-
ence of energy depletion on the cellular uptake pro-
cess, and of the P-glycoprotein- and MRP-substrates,
w xvincristine and DNP-SG, respectively, 23–25 , ob-
served in the current work, support such speculations.
Likewise, these observations provide the first clues to
the mechanism for one part of the found translocation
events.
The majority of the peptide transport described
here, however, proceeded by energy-independent
mechanisms. The energy independence, in conjunc-
tion with the levels of internalized peptide, approach-
ing an equilibrium between external and internal
concentrations, and the substantially reduced uptake
at 08C, point to facilitated diffusion as the mechanism
for this part of peptide translocation.
Non-specific adsorptive endocytosis or pinocytosis
can only partly explain the transport phenomena found
in the present study, taking into consideration the
high intracellular peptide levels attained and presum-
ing a total volume for endocytic vesicles of only
w xabout 10% of that of the entire cell 37 . An explana-
tion by these mechanisms is further compromised by
the observed high exchange rates, of the order of
minutes, considering that periods of 1–2 h are com-
monly required for the turnover of endocytic vesicles
between a cell’s interior and the plasma membrane
w x38 . Moreover, brefeldin A, an inhibitor of vesicular
w xtransport 28 , had no influence upon peptide uptake.
The very specific transporters for enkephalin-like
w xpeptides 8,9 can be ruled out as accounting for the
transport phenomena observed here, because of the
lack of saturability and poor structural specificity.
These features tempt one to speculate that the pep-
tides might be capable of exploiting transport facili-
ties that were originally destined for non-peptidic
substrates. Preliminary experiments point to amino
acid transporters and putative protein channels as
probable candidates for mediating such transport.
Other preliminary experiments suggest an analogy to
the behaviour of several membrane-permeable am-
phipathic peptides, which have been reported to ex-
tensively cross the plasma membrane of mammalian
w xcells by an unknown mechanism 39–41 . These is-
sues will be addressed in future studies.
This study provides evidence for the existence of
efficient and non-specific facilities for translocating
small peptides in the plasma membranes of mam-
malian cells. The ability of peptides to extensively
cross plasma membranes calls for altered strategies to
attain intracellular activity that consider not only
metabolic stability and propensity to traverse lipidic
membranes, the currently most widespread practice,
but also efforts to minimize peptide export out of the
cells.
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